FindTrial
Sign In

Analysis of influencing factors on voriconazole plasma concentration in patients with severe AECOPD complicated by invasive pulmonary aspergillosis

Analysis of influencing factors on voriconazole plasma concentration in patients with severe AECOPD complicated by invasive pulmonary aspergillosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600121132
Enrollment
Unknown
Registered
2026-03-26
Start date
2026-03-26
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious disease

Interventions

Infectious Disease Treatment Observation Group:None

Sponsors

Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. From January 2020 to February 2026, treated patients in the Intensive Care Unit of the Respiratory and Critical Care Medicine Department of Nanjing Gulou Hospital; 2. Diagnosed with acute exacerbation of chronic obstructive pulmonary disease; 3. Treated with voriconazole for invasive pulmonary aspergillosis; 4. Conducted monitoring of voriconazole blood concentration.

Exclusion criteria

Exclusion criteria: 1. Age less than 18 years old; 2. Patients with incomplete relevant clinical information.

Design outcomes

Primary

MeasureTime frame
Voriconazole plasma concentration;Administration frequency of voriconazole;Administration time and course of treatment of voriconazole;—

Countries

China

Contacts

Public ContactChen Xingkai

Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School

chxkabc@126.com+86 25 8310 6666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 4, 2026